| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vivo |
In the LyP-1-treated group, there is a notable 8-week decrease in the rates of both plaque occupancy and creation. Furthermore, compared to control peptide, a greater rate of apoptosis is seen in macrophages liberated from hypoxic plaques following LyP-1 treatment[1]. For optical imaging, a near-infrared fluorophore (Cy5.5) is used to identify the LyP-1 peptide. Tumor-bearing BALB/C mice are injected with Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of their upper extremities on days 3, 7, 14, and 21 following their inoculation with 4T1 cells. At days 3, 7, 14, and 21 following tumor cell inoculation, the fluorescence intensities were 0.024, 0.038, 0.048, and 0.106×106 photon/cm2/sec, respectively. These values are 1.02, 1.63, 2.04, and 4.52-fold greater than in the contralateral LNs. LyP-1 peptide binding specific to lymphatics is suggested by Cy5.5-LyP-1 staining in lymph nodes co-localizing with LYVE-1[1].
|
|---|---|
| References |
[1]. Fan Zhang, et al.Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51.
[2]. Ningning Song, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375. |
| Molecular Formula |
C36H65N17O12S2
|
|---|---|
| Molecular Weight |
992.138
|
| Exact Mass |
991.444
|
| CAS # |
454487-07-1
|
| Related CAS # |
LyP-1 TFA
|
| PubChem CID |
162678817
|
| Sequence |
Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys (Disulfide bridge: Cys1-Cys9)CGNKRTRGC (Disulfide bridge: Cys1-Cys9)
|
| SequenceShortening |
CGNKRTRGC (Disulfide bridge: Cys1-Cys9)
|
| Appearance |
White to off-white solid powder
|
| LogP |
-10.3
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
67
|
| Complexity |
1790
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CCCCN)CC(=O)N)N)C(=O)O)CCCN=C(N)N)O
|
| InChi Key |
CEKSIKGPDBMBEG-SLQNPQMPSA-N
|
| InChi Code |
InChI=1S/C36H65N17O12S2/c1-17(54)27-33(63)52-19(7-4-10-44-35(40)41)29(59)47-14-26(57)49-23(34(64)65)16-67-66-15-18(38)28(58)46-13-25(56)48-22(12-24(39)55)32(62)51-20(6-2-3-9-37)30(60)50-21(31(61)53-27)8-5-11-45-36(42)43/h17-23,27,54H,2-16,37-38H2,1H3,(H2,39,55)(H,46,58)(H,47,59)(H,48,56)(H,49,57)(H,50,60)(H,51,62)(H,52,63)(H,53,61)(H,64,65)(H4,40,41,44)(H4,42,43,45)/t17-,18+,19+,20+,21+,22+,23+,27+/m1/s1
|
| Chemical Name |
(4R,10S,13S,16S,19S,22S,28R)-28-amino-19-(4-aminobutyl)-22-(2-amino-2-oxoethyl)-10,16-bis[3-(diaminomethylideneamino)propyl]-13-[(1R)-1-hydroxyethyl]-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~100.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (2.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0079 mL | 5.0396 mL | 10.0792 mL | |
| 5 mM | 0.2016 mL | 1.0079 mL | 2.0158 mL | |
| 10 mM | 0.1008 mL | 0.5040 mL | 1.0079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
